Abuses against Women and Girls with Psychosocial or Intellectual Disabilities in institutions in India
Dermatologic Clinics Volume 29, Issue 1p1-8January 2011
Pharmaceuticals 2024, 17(6), 691; https://doi.org/10.3390/ph17060691
6 July 2021. Three new nucleic acid amplification test (NAAT) classes are endorsed by WHO and included.
The latest operational handbook includes the new classes recommended by WHO. It aims at facilitating the implementation of the WHO recommendations by the Member States, technical partners, and ot...hers involved in managing patients with TB and DR-TB. The operational handbook provides practical information on existing and new tests recommended by WHO, step-by-step advice on implementing and scale-up testing to achieve local and national impact and lastly, model diagnostic algorithms, which are updated to incorporate the latest recommendations. An overview of budgetary considerations and information sheets on each of the newly recommended tests is provided.
more
This year marked the beginning of the WHO biennium 2016-2017 action plan; this annual report highlights WHO’s key achievements in 2016
It also documents the extraordinary efforts by a broad coalition of government ministries, municipalities, international agencies, community groups, women’s or...ganizations, religious and traditional leaders, media, private sector and donors towards restoration and improving health indicators.
more
Collection of country-level good practices
Intégrer les activités communautaires de lutte contre la tuberculose dans le travail des ONG et des autres organisations de la société civile
Guide de l’animateur
Each year since 2007, G-FINDER has provided policy-makers, donors, researchers and industry with a comprehensive analysis of global investment into research and development of new products to
prevent, diagnose, control or cure neglected diseases in low- and middle-income countries, making it the go...ld standard in tracking and reporting global funding for neglected disease R&D. This year’s report, the sixteenth overall, focuses on investments made in participants’ 2022 financial year (‘FY2022’) and, for the first time, adds comprehensive coverage of the product pipeline in each disease area.
more